The Human Oral Microbiome by Floyd Dewhirst, Harvard University

submitted by: dougramsey
The human oral cavity is a diverse habitat that contains approximately bacterial 600 predominant species. The oral microbiome is comprised of 44% named species, 12% isolates representing unnamed species, and 44% phylotypes known only from 16S rRNA based cloning studies. Species from 11 phyla have been identified: Firmicutes (211), Bacteroidetes (106), Proteobacteria (99), Actinobacteria (64), Spirochaetes (49), Fusobacteria (29), TM7 (12), Synergistetes (10), Chlamydiae (1), Chloroflexi (1)...

New York-SGX Research Center for Structural Genomics

submitted by: dougramsey

Brief Report on Collaboration with Gerlt/Raushel P01 Consortium

Functional Health Literacy by Andrea Backes

submitted by: david868
Functional health literacy (FHL) is defined as the ability to read, understand, and act on health information.1 The Institute of Medicine estimates that nearly half of all American adults lack these crucial skills, which prevent them from functioning effectively and safely in today’s complex healthcare system.2 Previous studies have shown that patients with low FHL are less likely to comprehend written patient education materials on their chronic disease state and are more likely to...

Kleine Pixel, grosse Samples

submitted by: habi

Lecture on my work over the past months. http://is.gd/874S htt://is.gd.874Y http://www.psi.ch/medien http://www.scanco.ch

Scripps Translational Science Institute - Welcome Video

submitted by: STSI-Admin

The Scripps Translational Science Institute (STSI), in conjunction with the National Institutes of Health (NIH) Translational Science Award (CTSA) Consortium is transforming how clinical and translational research is conducted, ultimately enabling researchers to provide new treatments more efficiently and quickly to patients. For more information see: http://www.stsiweb.org/

Drug Discovery for Alzheimer's Disease

submitted by: alex01

Gregory Rose from PharmExperts.com interviews J. Buccafusco (Medical College of Georgia, Augusta, GA) about his development of new anti-Altzheimer drugs, designed to act by multiple mechanisms to improve congnition. Desensitization of nicotinic receptors is one of the novel approaches proposed by Buccafusco. Three of his compounds are currently in advanced preclinical evaluation.